We are a molecular genetics cancer diagnostic company formed in 2021 to acquire PharmGenomics GmbH (“PharmGenomics“) with the purpose of commercializing their product portfolio in Europe and the United States. PharmGenomics has developed several IVD tests for the European market since it was founded in 2008.

Our portfolio includes ColoAlert, a colorectal cancer (“CRC”) screening stool DNA test licensed from ColoAlert AS and sold in Europe, and PancAlert, a product candidate in an early stage of research for a pancreatic cancer screening test based on Real-Time Polymerase Chain Reaction (“PCR”)-based multiplex detection of molecular genetic biomarkers in stool samples.

CRC refers to malignant tumors in the colon or rectum. These tumors usually develop from benign polyps which, over time degenerate and become cancerous. Because of the high survival rates in case of early detection, regular and accurate screening is essential.

According to the American Cancer Society, CRC is the third most commonly diagnosed cancer, but the second leading cause of cancer death in the world.

(Note: Mainz Biomed priced its IPO on Nov. 4, 2021, at $5 – the mid-point of its $4-to-$6 range – on 2 million shares to raise $10 million. The deal was delayed for a little more than a day by a last-minute regulatory review.)